The future of cancer treatment and drug development relies on recognizing that each tumor is different. Partnering with Gustave Roussy, the world's 3rd best cancer center, Orakl enables the emergence of rare oncology by connecting patient tumors to the drug discovery industry. Orakl leverages tumor avatars that combine best-in-class biology with deep patient data, at scale. Our techbio platform partners with oncology players to identify relevant targets and deliver better drugs, faster.
Something looks off?